These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9853232)

  • 21. WITHDRAWN: Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Autenrieth M; Kumpf J; Coldman A; Wilt TJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD001425. PubMed ID: 26713838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunotherapy for advanced renal cell cancer].
    Schmidt S; Kunath F; Kroeger N
    Urologe A; 2015 May; 54(5):716-20. PubMed ID: 25987336
    [No Abstract]   [Full Text] [Related]  

  • 23. A case of renal cell carcinoma with bone and lymph node metastases.
    Di Seri M; Verì A; Colloca M; Spalletta B; Rossi R; Petrella PP; Coletta D; Petricola F; Ricciardi S; Frati L
    Tumori; 2003; 89(4):437-9. PubMed ID: 14606651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.
    Bukowski RM
    Cancer; 1997 Oct; 80(7):1198-220. PubMed ID: 9317170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
    Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
    Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases.
    Rini BI; Shaw V; Rosenberg JE; Kim ST; Chen I
    Clin Genitourin Cancer; 2006 Dec; 5(3):232-4. PubMed ID: 17239278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of donor melanoma in a renal transplant recipient.
    Wilson LJ; Horvat RT; Tilzer L; Meis AM; Montag L; Huntrakoon M
    Diagn Mol Pathol; 1992 Dec; 1(4):266-71. PubMed ID: 1364174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
    Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
    J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral blood neutrophils as independent immunologic predictor of response and long-term survival upon immunotherapy in metastatic renal-cell carcinoma.
    Atzpodien J; Reitz M
    Cancer Biother Radiopharm; 2008 Feb; 23(1):129-34. PubMed ID: 18298337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is preoperative embolization a prerequisite for spinal metastases surgical management?
    Robial N; Charles YP; Bogorin I; Godet J; Beaujeux R; Boujan F; Steib JP
    Orthop Traumatol Surg Res; 2012 Sep; 98(5):536-42. PubMed ID: 22809704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastatic renal-cell carcinoma: what causes occasional dramatic regressions?
    Young RC
    N Engl J Med; 1998 Apr; 338(18):1305-6. PubMed ID: 9562587
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment.
    Taneja SS; Pierce W; Figlin R; Belldegrun A
    Urology; 1995 Jun; 45(6):911-24. PubMed ID: 7771023
    [No Abstract]   [Full Text] [Related]  

  • 35. [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology].
    van Herpen CM; de Mulder PH
    Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2613-8. PubMed ID: 10028361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A case report of renal cell carcinoma with bilateral adrenal metastases].
    Miyamoto S; Higashi H; Okamura K; Matsuo Y; Kobayashi M; Yamanaka H
    Hinyokika Kiyo; 1997 Feb; 43(2):127-30. PubMed ID: 9086348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Has interleukin 2 modified the outcome of metastatic kidney cancer?].
    Négrier S; Philip T
    Ann Urol (Paris); 1993; 27(2):87-9. PubMed ID: 8503657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy of metastatic renal cell cancer.
    Fishman M; Seigne J
    Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).
    Pandha H
    Integr Cancer Ther; 2004 Mar; 3(1):29-34. PubMed ID: 15035872
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.